메뉴 건너뛰기




Volumn 73, Issue 4, 2012, Pages 983-992

New anticoagulants: A concise review

Author keywords

Anticoagulation; apixaban; dabigatran; rivaroxaban; thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; APIXABAN; BLOOD CLOTTING FACTOR 9 COMPLEX; COFACT; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; WARFARIN;

EID: 84867090302     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318265cf9e     Document Type: Review
Times cited : (29)

References (54)
  • 2
    • 79957715797 scopus 로고    scopus 로고
    • Anticoagulant optionsVwhy the FDA approved a higher but not a lower dose of dabigatran
    • Beasley BN, Unger EF, Temple R. Anticoagulant optionsVwhy the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788-1790.
    • (2011) N Engl J Med. , vol.364 , pp. 1788-1790
    • Beasley, B.N.1    Unger, E.F.2    Temple, R.3
  • 3
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilateVa novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilateVa novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
    • (2010) Thromb Haemost. , vol.103 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3    Liesenfeld, K.H.4    Wienen, W.5    Feuring, M.6    Clemens, A.7
  • 4
    • 77956977472 scopus 로고    scopus 로고
    • Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial f ibrillation: An analysis of the RE-LY trial
    • and RE-LY Investigators
    • Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, et al, and RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial f ibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376:975-983.
    • (2010) Lancet. , vol.376 , pp. 975-983
    • Wallentin, L.1    Yusuf, S.2    Ezekowitz, M.D.3    Alings, M.4    Flather, M.5    Franzosi, M.G.6    Pais, P.7    Dans, A.8    Eikelboom, J.9    Oldgren, J.10
  • 5
    • 80052232522 scopus 로고    scopus 로고
    • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial
    • RE-DEEM Investigators
    • Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L, RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781-2789.
    • (2011) Eur Heart J. , vol.32 , pp. 2781-2789
    • Oldgren, J.1    Budaj, A.2    Granger, C.B.3    Khder, Y.4    Roberts, J.5    Siegbahn, A.6    Tijssen, J.G.7    Van De Werf, F.8    Wallentin, L.9
  • 6
    • 77957029781 scopus 로고    scopus 로고
    • Dabigatran etexilate: Pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty
    • Eriksson BI, Friedman RJ. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009;15(suppl 1):25S-31S.
    • (2009) Clin Appl Thromb Hemost. , vol.15 , Issue.SUPPL. 1
    • Eriksson, B.I.1    Friedman, R.J.2
  • 7
    • 79953836474 scopus 로고    scopus 로고
    • Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, noninferiority trial
    • RE-NOVATE II Study Group
    • Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, noninferiority trial. Thromb Haemost. 2011;105:721-729.
    • (2011) Thromb Haemost. , vol.105 , pp. 721-729
    • Eriksson, B.I.1    Dahl, O.E.2    Huo, M.H.3    Kurth, A.A.4    Hantel, S.5    Hermansson, K.6    Schnee, J.M.7    Friedman, R.J.8
  • 9
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • DOI 10.1111/j.1365-2125.2007.02899.x
    • Stangier J, Rathgen K, Stahle H, Gansser D, RothW. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303. (Pubitemid 47283865)
    • (2007) British Journal of Clinical Pharmacology , vol.64 , Issue.3 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3    Gansser, D.4    Roth, W.5
  • 17
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
    • RECORD2 Investigators
    • Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
    • (2008) Lancet. , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3    Eriksson, B.I.4    Mouret, P.5    Muntz, J.6    Soglian, A.G.7    Pap, A.F.8    Misselwitz, F.9    Haas, S.10
  • 20
    • 79957619172 scopus 로고    scopus 로고
    • Asystematic reviewof rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement
    • Turun S, Banghua L, YuanY, Zhenhui L, YingN, Jin C.Asystematic reviewof rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res. 2011;127:525-534.
    • (2011) Thromb Res. , vol.127 , pp. 525-534
    • Turun, S.1    Banghua, L.2    Yuan, Y.3    Zhenhui, L.4    Ying, N.5    Jin, C.6
  • 22
    • 79960068693 scopus 로고    scopus 로고
    • Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time
    • Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost. 2011;106:156-164.
    • (2011) Thromb Haemost. , vol.106 , pp. 156-164
    • Mani, H.1    Hesse, C.2    Stratmann, G.3    Lindhoff-Last, E.4
  • 27
    • 67649563209 scopus 로고    scopus 로고
    • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    • APPRAISE Steering Committee and Investigators
    • Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, et al, APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-2885.
    • (2009) Circulation. , vol.119 , pp. 2877-2885
    • Alexander, J.H.1    Becker, R.C.2    Bhatt, D.L.3    Cools, F.4    Crea, F.5    Dellborg, M.6    Fox, K.A.7    Goodman, S.G.8    Harrington, R.A.9    Huber, K.10
  • 30
    • 77649113258 scopus 로고    scopus 로고
    • Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomized double-blind trial
    • ADVANCE-2 Investigators
    • LassenMR, RaskobGE, GallusA, Pineo G, ChenD, Hornick P, ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375:807-815.
    • (2010) Lancet. , vol.375 , pp. 807-815
    • Lassen, M.R.1    Raskob, G.E.2    Gallus, A.3    Pineo, G.4    Chen, D.5    Hornick, P.6
  • 32
    • 80052502475 scopus 로고    scopus 로고
    • Chromogenic laboratory assays to measure the factor XaYinhibiting properties of apixabanVan oral, direct and selective factor Xa inhibitor
    • Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor XaYinhibiting properties of apixabanVan oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183-187.
    • (2011) J Thromb Thrombolysis. , vol.32 , pp. 183-187
    • Becker, R.C.1    Yang, H.2    Barrett, Y.3    Mohan, P.4    Wang, J.5    Wallentin, L.6    Alexander, J.H.7
  • 34
    • 80052351015 scopus 로고    scopus 로고
    • Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    • Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31:478-492.
    • (2011) J Thromb Thrombolysis. , vol.31 , pp. 478-492
    • Wong, P.C.1    Pinto, D.J.2    Zhang, D.3
  • 35
    • 77649221986 scopus 로고    scopus 로고
    • Hemostatic resuscitation for massive bleeding: The paradigm of plasma and plateletsVa review of the current literature
    • Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and plateletsVa review of the current literature. Transfusion. 2010;50:701-710.
    • (2010) Transfusion. , vol.50 , pp. 701-710
    • Johansson, P.I.1    Stensballe, J.2
  • 36
    • 79953163189 scopus 로고    scopus 로고
    • The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomized controlled trial
    • 1101e1-e2 Crash-2 Investigators
    • CRASH-2 Investigators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomized controlled trial. Lancet. 2011; 377:1096-1101, 1101.e1-e2.
    • (2011) Lancet. , vol.377 , pp. 1096-1101
    • Roberts, I.1    Shakur, H.2    Afolabi, A.3    Brohi, K.4    Coats, T.5    Dewan, Y.6    Gando, S.7    Guyatt, G.8    Hunt, B.J.9
  • 37
    • 84865581160 scopus 로고    scopus 로고
    • Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients
    • April 27. [ePub ahead of print]
    • Clav A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients. Orthop Traumatol Surg Res. 2012 April 27. [ePub ahead of print].
    • (2012) Orthop Traumatol Surg Res.
    • Clav, A.1    Fazilleau, F.2    Dumser, D.3    Lacroix, J.4
  • 38
    • 84856784474 scopus 로고    scopus 로고
    • Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosisVAmerican College of Chest Physicians evidence-based clinical practice guidelines
    • American College of Chest Physicians
    • Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosisVAmerican College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S-e88S.
    • (2012) Chest. , vol.141
    • Ageno, W.1    Gallus, A.S.2    Wittkowsky, A.3    Crowther, M.4    Hylek, E.M.5    Palareti, G.6
  • 39
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
    • Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
    • (2011) Circulation. , vol.124 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3    Meijers, J.C.4    Buller, H.R.5    Levi, M.6
  • 40
    • 84858755308 scopus 로고    scopus 로고
    • The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation
    • van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood. 2011;118:2316.
    • (2011) Blood. , vol.118 , pp. 2316
    • Van Ryn, J.1    Schurer, J.2    Kink-Eiband, M.3    Clemens, A.4
  • 42
  • 43
    • 78649980897 scopus 로고    scopus 로고
    • Pharmacologic properties of the new oral anticoagulants: A clinician-oriented review with a focus on perioperative management
    • Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16:3436-3441.
    • (2010) Curr Pharm Des. , vol.16 , pp. 3436-3441
    • Douketis, J.D.1
  • 45
    • 13244266944 scopus 로고    scopus 로고
    • Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
    • DOI 10.1111/j.1538-7836.2004.00890.x
    • Eriksson BI, Dahl OE, Ahnfelt L, Kä lebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2:1573-1580. (Pubitemid 40186173)
    • (2004) Journal of Thrombosis and Haemostasis , vol.2 , Issue.9 , pp. 1573-1580
    • Eriksson, B.I.1    Dahl, O.E.2    Ahnfelt, L.3    Kalebo, P.4    Stangier, J.5    Nehmiz, G.6    Hermansson, K.7    Kohlbrenner, V.8
  • 46
    • 17644409026 scopus 로고    scopus 로고
    • A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
    • DOI 10.1111/j.1538-7836.2004.01100.x
    • Eriksson BI, Dahl OE, Bller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, et al, BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-111. (Pubitemid 41647122)
    • (2005) Journal of Thrombosis and Haemostasis , vol.3 , Issue.1 , pp. 103-111
    • Eriksson, B.I.1    Dahl, O.E.2    Buller, H.R.3    Hettiarachi, R.4    Rosencher, N.5    Bravo, M.-L.6    Ahnfelt, L.7    Piovella, F.8    Stangier, J.9    Kalebo, P.10    Reilly, P.11
  • 48
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
    • DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
    • Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, et al, RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, noninferiority trial. Lancet. 2007;370:949-956. (Pubitemid 47393577)
    • (2007) Lancet , vol.370 , Issue.9591 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3    Kurth, A.A.4    Van Dijk, C.N.5    Frostick, S.P.6    Prins, M.H.7    Hettiarachchi, R.8    Hantel, S.9    Schnee, J.10    Buller, H.R.11
  • 49
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • RE-MOBILIZE Writing Committee
    • Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, et al, RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
    • (2009) J Arthroplasty. , vol.24 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2    Comp, P.C.3    Francis, C.W.4    Friedman, R.J.5    Huo, M.H.6    Lieberman, J.R.7    Muntz, J.E.8    Raskob, G.E.9    Clements, M.L.10
  • 51
    • 34447317298 scopus 로고    scopus 로고
    • Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study
    • DOI 10.1161/CIRCULATIONAHA.106.668020
    • Agnelli G, Gallus A, Goldhaber SZ, Haas S, HuismanMV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-187. (Pubitemid 47057524)
    • (2007) Circulation , vol.116 , Issue.2 , pp. 180-187
    • Agnelli, G.1    Gallus, A.2    Goldhaber, S.Z.3    Haas, S.4    Huisman, M.V.5    Hull, R.D.6    Kakkar, A.K.7    Misselwitz, F.8    Schellong, S.9
  • 52
    • 78650587760 scopus 로고    scopus 로고
    • Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
    • ADVANCE-3 Investigators
    • Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.
    • (2010) N Engl J Med. , vol.363 , pp. 2487-2498
    • Lassen, M.R.1    Gallus, A.2    Raskob, G.E.3    Pineo, G.4    Chen, D.5    Ramirez, L.M.6
  • 53
    • 47649098524 scopus 로고    scopus 로고
    • Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    • DOI 10.1111/j.1538-7836.2008.03054.x
    • Botticelli Investigators, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313-1318. (Pubitemid 352016310)
    • (2008) Journal of Thrombosis and Haemostasis , vol.6 , Issue.8 , pp. 1313-1318
    • Buller, H.1    Deitchman, D.2    Prins, M.3    Segers, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.